– CANADA, Brossard – Diagnos Inc. (TSX:ADK | OTCQB:DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence, today announced the appointment of Dr. Jean-Francois Yale to its board of directors.

“We are delighted to have Dr. Yale joining the Board. I am convinced that DIAGNOS will greatly benefit from his specialized interest in intensive management of type 1 and type 2 diabetes,” said Mr. Georges Hebert, Chairman of the board of directors of DIAGNOS.

About Dr Jean-Francois Yale

Dr. Yale is an endocrinologist, currently professor of medicine at the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992-1994 as well as the Expert Committee that published the 2001 Clinical Practice Guidelines for the Prevention and Management of Diabetes. Dr. Yale’s research interests (210 publications) include the prevention of hypoglycemia in type 1 diabetes and he participated in numerous multicentre trials on new therapies for type 1 and type 2 diabetes.

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.

For more information : http://www.diagnos.ca

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.